公开(公告)号：US20030225145A1

公开(公告)日：2003-12-04

申请号：US10428096

申请日：2003-05-02

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Hisao Tajima ,  Yoshisuke Nakayama ,  Daikichi Fukushima

IPC分类号： C07D417/02 ,  C07D413/02 ,  C07D49/02 ,  C07D45/02 ,  A61K031/427 ,  A61K031/422 ,  A61K031/4178

CPC分类号： C07D413/06 ,  C07D413/14 ,  C07D417/06

摘要： A peroxisome proliferator activated receptor regulator containing a compound of formula (I) 1 (wherein all symbols are as defined in the specification), or a salt thereof as active ingredient. Because of having an effect of regulating PPAR, a compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive and/or a remedy for diseases associating metabolic disorders (diabetes, obesity, syndrome X, hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipemia, atherosclerosis, hypertension, circulatory diseases, overeating, coronary heart diseases, etc., an HDL cholesterol-elevating agent, an LDL cholesterol and/or VLDL cholesterol-lowering agent and a drug for relief from risk factors of diabetes or syndrome X.

摘要翻译： 含有式（I）化合物（其中所有符号如说明书中所定义）的过氧化物酶体增殖物激活受体调节剂或其盐作为活性成分。 由于具有调节PPAR的作用，式（I）化合物可用作降血糖剂，​​降血脂药，用于代谢紊乱（糖尿病，肥胖症，综合征X，高胆固醇血症，高脂蛋白血症）的疾病的预防和/或补救措施 等），高脂血症，动脉粥样硬化，高血压，循环系统疾病，暴饮暴食，冠心病等，HDL胆固醇升高剂，LDL胆固醇和/或VLDL胆固醇降低剂和用于缓解危险因素的药物 糖尿病或综合症。

公开(公告)号：US20030153579A1

公开(公告)日：2003-08-14

申请号：US10251805

申请日：2002-09-23

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Hisao Tajima ,  Yoshisuke Nakayama ,  Daikichi Fukushima

IPC分类号： A61K031/497 ,  A61K031/445 ,  A61K031/277 ,  A61K031/192

CPC分类号： C07D213/30 ,  A61K31/00 ,  C07C59/66 ,  C07C59/68 ,  C07C59/72 ,  C07C323/52 ,  C07D213/65 ,  C07D263/32 ,  C07D263/34 ,  C07D263/48 ,  C07D277/24 ,  C07D317/54 ,  C07D413/04 ,  C07D413/10 ,  C07D417/04 ,  C07D417/10

摘要： A peroxisome proliferator activated receptor regulator containing a carboxylic acid derivative of formula (I) 1 (wherein all symbols are as defined in the specification), a non-toxic acid thereof or a hydrate thereof as active ingredient. Because of having an effect of regulating PPAR, a compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive and/or a remedy for diseases associating metabolic disorders (diabetes, obesity, syndrome X, hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipemia, atherosclerosis, hypertension, circulatory diseases, overeating, coronary heart diseases, etc., an HDL cholesterol-elevating agent, an LDL cholesterol and/or VLDL cholesterol-lowering agent and a drug for relief from risk factors of diseases or syndrome X.

摘要翻译： 含有式（I）的羧酸衍生物（其中所有符号如说明书中所定义），其无毒性酸或其水合物作为活性成分的过氧化物酶体增殖物激活受体调节剂。 由于具有调节PPAR的作用，式（I）化合物可用作降血糖剂，​​降血脂药，用于代谢紊乱（糖尿病，肥胖症，综合征X，高胆固醇血症，高脂蛋白血症）的疾病的预防和/或补救措施 等），高脂血症，动脉粥样硬化，高血压，循环系统疾病，暴饮暴食，冠心病等，HDL胆固醇升高剂，LDL胆固醇和/或VLDL胆固醇降低剂和用于缓解危险因素的药物 疾病或综合征X.

公开(公告)号：US20040087636A1

公开(公告)日：2004-05-06

申请号：US10464459

申请日：2003-06-19

申请人： ONO PHARMACEUTICAL CO., LTD.

发明人： Hisao Tajima ,  Yoshisuke Nakayama ,  Daikichi Fukushima

IPC分类号： C07D413/02 ,  A61K031/422

CPC分类号： C07D413/04 ,  C07D263/32 ,  C07D493/08

摘要： A peroxisome proliferator activated receptor regulator containing a carboxylic acid derivative of formula (I) 1 (wherein all symbols are as defined in the specification), a non-toxic acid thereof or a hydrate thereof as active ingredient. Because of having an effect of regulating PPAR, a compound of formula (I) is useful as a hypoglycemic agent, a hypolipidemic agent, a preventive and/or a remedy for diseases associating metabolic disorders (diabetes, obesity, syndrome X, hypercholesterolemia, hyperlipoproteinemia, etc.), hyperlipemia, atherosclerosis, hypertension, circulatory diseases, overeating, coronary heart diseases, etc., an HDL cholesterol-elevating agent, an LDL cholesterol and/or VLDL cholesterol-lowering agent and a drug for relief from, risk factors of diabetes or syndrome X.

摘要翻译： 含有式（I）的羧酸衍生物（其中所有符号如说明书中所定义），其无毒性酸或其水合物作为活性成分的过氧化物酶体增殖物激活受体调节剂。 由于具有调节PPAR的作用，式（I）化合物可用作降血糖剂，​​降血脂药，用于代谢紊乱（糖尿病，肥胖症，综合征X，高胆固醇血症，高脂蛋白血症）的疾病的预防和/或补救措施 等），高脂血症，动脉粥样硬化，高血压，循环系统疾病，暴饮暴食，冠心病等，HDL胆固醇升高剂，LDL胆固醇和/或VLDL胆固醇降低剂和用于缓解危险因素的药物 的糖尿病或综合症。